Anonymousabout 4 hours ago
The CDC has issued new warnings about drug-resistant bacteria, including a 460% surge in NDM-CRE infections between 2019 and 2023. The COVID-19 pandemic reversed years of progress, driving a 20% increase in hospital-onset resistant infections, while the antibiotic development pipeline continues to shrink — only four new antibiotics received FDA approval between 2020 and 2024, compared to 29 in the 1980s. The burden falls disproportionately on low-income and minority communities, and structural market failures have driven most major pharmaceutical companies out of antibiotic research entirely.